1 – 5 of 5
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Exploring the interplay between antiretroviral therapy and the gut-oral microbiome axis in people living with HIV
(
- Contribution to journal › Article
- 2023
-
Mark
Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV
(
- Contribution to journal › Article
- 2013
-
Mark
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naive HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial
(
- Contribution to journal › Article
- 2011
-
Mark
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naive HIV-1 infected patients
(
- Contribution to journal › Article
- 2010
-
Mark
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-na
- Contribution to journal › Article